Aromyx Corporation

Digitizing the sense of smell

  • Stage $500K in TTM Revenue
  • Industry Software
  • Location Palo Alto, CA, US
  • Currency USD
  • Founded May 2014
  • Employees 14
  • Incorporation Type C-corp
  • Website aromyx.com

Company Summary

Aromyx is a Stanford StartX & DARPA-backed, pre-Series A company with CRISPR-constructed proprietary sensing and AI that digitizes the human sense of smell and taste. We use it to dramatically increases yields in biologic drug fermentation and production, where we have a $250,000 R&D program with one of the largest pharma companies. We use it in agriculture, where we have a similar-sized pilot program with one of the largest ag companies.

Team

  • IBM, Seagate, DOD, NSA, 4 prior startups, 2 successful exits. Track record of large sales. Stanford University BA, MA. Helped start cognitive computing development at IBM. Put together government research funding for the IBM Research program to reverse engineer the human brain, and to design and build a chip that mimics synapses in the human brain. Led commercialization efforts for the new neurosynaptic 'brain' chip and software infrastructure.

  • Board member, inventor of the chip

    SRI, prior startups, inventor of this biosensor. Has also founded companies, most notably Target Discovery, a successful biotech firm.

  • Chief Scientific Officer

    Dr. Bill Harries, our Chief Scientist, was before Aromyx the acting chief scientific officer of the Center for Structures of Membrane Proteins (CSMP) at the University of California San Francisco, where he was responsible for developing state of the art membrane protein expression, purification, crystallization, and structure determination methods and instrumentation.

  • Vice President, Engineering

    Has been building complex systems and the software that drives them for over 20 years. Most recently, he has led large-scale programs at Adobe Systems and at HP.

  • Board member

    Biotech entrepreneur, former VC with Sequel Ventures, Guidant, Bayer Pharmaceuticals.

  • Dr. Danny Dhanasekaran
    Science Advisor

    Dr. Dhanasekaran has led groundbreaking research teams in the study of the biology and behavior of olfactory receptors. He serves as Director of the Center for Basic Cancer Research at Oklahoma University Cancer Institute and Editor-in-Chief of the Journal of Molecular Signaling. He is also a professor in the cell biology department in the University of Oklahoma College of Medicine at the OU Health Sciences Center.

  • Todd Cushman
    Vice President, Sales

    15 years IT, data, software, pharma sales to large accounts. IBM, Zeneca Pharmaceuticals.

  • Dr. James Broach
    Science Advisor

    Dr. Broach pioneered seminal work in the science and biology of olfaction. He is Chair of the Department of Biochemistry and Molecular Biology at Penn State Hershey, Director of the Penn State Institute for Personalized Medicine and Professor Emeritus of Princeton University.

  • Dr. Robert Stroud
    Science Advisor

    Professor of Biochemistry & Biophysics , Professor of Pharmaceutical Chemistry , member of the Macromolecular Structure Group, Department of Biochemistry & Biophysics at the University of California San Francisco.

Advisors

  • VC, Board Member of Tivo, Daily Mail and General Trust, Educator, Recovering Entrepreneur. Currently venture partner at Draper Fisher Jurvetson.
    Professor of Food Chemistry, Oregon State University
    Smell scientist, consultant, and author
  • Consulting Winemaker
    Attorney

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free